Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 2/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | NCF1 | P14598 | 3/20 | 0.52 |
| ▸ | CHKA | P35790 | 3/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CACNA2D1 | P54289 | 5/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109344 | 0.94 | AGXT (0.69) | AGXTADRA2CNCF1CHKAPRMT6 | |
| SCHEMBL109316 | 0.85 | AGXT (0.67) | AGXTNCF1CHKAPRMT6 | |
| SCHEMBL27662780 | 0.85 | AGXT (0.56) | AGXTADRA2CNCF1PRMT6 | |
| SCHEMBL24026846 | 0.85 | CHKA (0.68) | AGXTADRA2CNCF1CHKAPRMT6 | |
| SCHEMBL113454 | 0.84 | CHKA (0.71) | AGXTADRA2CNCF1CHKAPRMT6 | |
| SCHEMBL113799 | 0.84 | AGXT (0.65) | AGXTNCF1CHKAPRMT6 | |
| SCHEMBL5095800 | 0.84 | AGXT (0.65) | AGXTNCF1CHKAPRMT6 | |
| SCHEMBL5790198 | 0.81 | AGXT (0.66) | AGXTADRA2CPRMT6HTR3A | |
| SCHEMBL2649456 | 0.81 | ADRA2C (0.86) | AGXTADRA2CNCF1CHKACACNA2D1 | |
| SCHEMBL8189615 | 0.79 | AGXT (0.67) | AGXTADRA2CPRMT6HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349836-B2 | Phthalazine derivatives as inhibitors of protein kinase | ARALDI GIAN-LUCA (US) | 2013-01-08 | — | — | US | disclosed |
| US-8044041-B2 | e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-25 | — | — | US | disclosed |
| US-20110237571-A1 | PHTHALAZINE DERIVATIVES | ARALDI GIAN-LUCA | 2011-09-29 | — | — | US | disclosed |
| EP-2131656-A2 | PHTHALAZINE DERIVATIVES | Forest Laboratories Holdings Limited (BM) | 2009-12-16 | — | — | EP | disclosed |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-19 | — | — | US | disclosed |
| WO-2008061108-A2 | PHTHALAZINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237571-A1 | PHTHALAZINE DERIVATIVES | CDK5, HIPK2, PACSIN2 | AGXT 4241/4885ADRA2C 3844/4885NCF1 1108/4885 |
| US-20080146547-A1 | PHTHALAZINE DERIVATIVES | CDK5, HIPK2, PACSIN2 | AGXT 4241/4885ADRA2C 3844/4885NCF1 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.